Dingwei Ye
Shanghai Medical College of Fudan University(CN)Sun Yat-sen University(CN)Changchun Normal University(CN)Fudan University(CN)Fudan University Shanghai Cancer Center(CN)Shanghai Cancer Institute(CN)Zhejiang University(CN)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Renal cell carcinoma treatment, Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, Genital Health and Disease
Most-Cited Works
- → Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma(2023)431 cited
- → Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas(2012)383 cited
- → Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial(2018)254 cited
- → Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer(2015)164 cited
- → Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial(2019)115 cited
- → Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma(2020)113 cited